CJC-1295 5mg

What is CJC-1295 ?

CJC-1295 without DAC, also sold as modified GRF (1-29) or Mod GRF 1-29, is a 29 amino acid analogue of growth hormone releasing hormone. It acts at the GHRH receptor on pituitary somatotrophs. We supply it as a 5mg vial of lyophilised powder.

Compared with native GHRH (1-29), CJC-1295 without DAC carries four substitutions: D-Ala2, Gln8, Ala15 and Leu27. The formula is C₁₅₂H₂₅₂N₄₄O₄₂, the molecular weight 3367.9 g/mol and the CAS number 863288-34-0.

Plasma dipeptidyl peptidase IV inactivates native GHRH by cutting the bond between residues 2 and 3. A D-amino acid at position 2 blocks that cut (Frohman et al., J Clin Invest, 1989). The code CJC-1295 first named ConjuChem's DAC-bearing molecule. Sellers now use it for both forms, so check the mass on the certificate.

CJC-1295 Research Applications

CJC-1295 without DAC is used in GHRH receptor pharmacology, somatotroph cell studies and GH release kinetics. It is the usual GHRH-side partner in two-receptor designs with a ghrelin-receptor agonist such as ipamorelin. The human studies cited here used the DAC form, so check which molecule a paper used.

CJC-1295 No-DAC vs CJC-1295 DAC

Both share the tetrasubstituted GRF (1-29) chain and act at the GHRH receptor. The DAC form adds a C-terminal lysine carrying a maleimidopropionamide group, which binds Cys34 of serum albumin. In rats that conjugate was still in plasma after 72 hours (Jetté et al., Endocrinology, 2005).

In healthy adults the DAC form had a half-life of 5.8 to 8.1 days (Teichman et al., 2006). GH secretion stayed pulsatile under that continuous stimulation, with trough levels up 7.5-fold (Ionescu and Frohman, 2006). The no-DAC form has no albumin anchor, so it suits short, pulse-like stimulation. At 3647.2 against 3367.9 g/mol, mass spectrometry tells the two apart.

Research Overview

CJC-1295 (no DAC) is a synthetic analogue of growth hormone releasing hormone (GHRH), also referred to as modified GRF 1-29. It binds to GHRH receptors in the anterior pituitary gland to stimulate the synthesis and secretion of growth hormone. The no DAC (Drug Affinity Complex) version lacks the maleimidopropionic acid linker present in CJC-1295 with DAC, resulting in a shorter half-life that produces more pulsatile GH release patterns. Researchers consider this pulsatile pattern more physiologically similar to natural endogenous GH secretion, making CJC-1295 no DAC particularly valuable for studies requiring physiological GH release kinetics. The compound is frequently studied in combination with Ipamorelin, a selective GHS-R1a agonist, for synergistic effects through complementary receptor pathways, CJC-1295 stimulating GH release via the GHRH receptor while Ipamorelin acts at the ghrelin receptor. This dual-pathway approach produces amplified GH pulses and has become a standard research protocol in growth hormone biology. Studies have examined CJC-1295's effects on plasma GH levels, IGF-1 production, body composition, and sleep-related GH secretion patterns.

The naming around this compound is genuinely confused across the research-chemical market and is worth untangling, because it affects which papers actually apply. CJC-1295 as originally developed by ConjuChem was the DAC-bearing molecule, the drug affinity complex being the defining feature of the compound that carried that code. What is universally sold as “CJC-1295 without DAC” is more accurately tetrasubstituted GRF(1-29), a GHRH fragment carrying D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. The substitution that does the real work is D-Ala2, which blocks cleavage by dipeptidyl peptidase-4, the protease that degrades native GHRH within minutes.

The practical consequence is that a good deal of literature cited for “CJC-1295 no DAC” is in fact about the DAC molecule, about mod GRF(1-29), or about native GHRH. Teichman and colleagues (J Clin Endocrinol Metab, 2006), the most frequently cited clinical work, studied the DAC-bearing version, whose sustained albumin-bound profile is not the pulsatile profile this vial produces. Researchers reading around the compound should check which molecule a given paper actually used.

Neither version holds a marketing authorisation in any jurisdiction; ConjuChem's clinical programme did not reach approval.

Storage and Reconstitution

Store CJC-1295 powder at -20°C, away from light and moisture, for up to 24 months. After reconstitution, keep the solution at 2-8°C and use it within 4 weeks. For longer storage, freeze single-use aliquots at -20°C and avoid repeated freeze-thaw cycles.

Vials are sold on their own, without bacteriostatic water for mixing or other supplies.

How to reconstitute and handle

Let the vial and the bacteriostatic water reach room temperature and swab both stoppers with alcohol. Add the water slowly down the inside wall of the vial and swirl gently until dissolved. Do not shake or vortex. The solution should be clear and colourless.

• Maintain strict aseptic technique. Sterilise vial stoppers with 70% isopropyl alcohol before each needle insertion.
• Prepare single-use aliquots from reconstituted stock. Repeated freeze-thaw cycling degrades GHRH analogue peptides.

For the full method, see the peptide reconstitution guide and the reconstitution calculator.

Research References

• Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults (Teichman et al., J Clin Endocrinol Metab, 2006; DAC form)
• Systemic and local regulation of the growth plate (van der Eerden et al., Endocr Rev, 2003)
• Dipeptidylpeptidase IV and trypsin-like degradation of GHRH in plasma (Frohman et al., J Clin Invest, 1989)
• hGRF(1-29)-albumin bioconjugates: identification of CJC-1295 as a long-lasting GRF analog (Jetté et al., Endocrinology, 2005)
• Pulsatile GH secretion persists during continuous stimulation by CJC-1295 (Ionescu and Frohman, J Clin Endocrinol Metab, 2006)
• GH-releasing peptide and GHRH in normal men (Bowers et al., J Clin Endocrinol Metab, 1990)

Published research on CJC-1295 is indexed on PubMed. See our full UK buyer's guide for CJC-1295 and UK buyer's guide for CJC-1295 CoA.